Nafcillin for Injection Recalled Nationwide for Lack of Sterility Assurance
Sagent Pharmaceuticals has recalled Nafcillin for Injection due to lack of sterility assurance. The recall affects approximately 370,200 bottles distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II injectable drug recall due to lack of sterility assurance. No illnesses or injuries reported, but this qualifies as a risk-of-harm product where injury has not yet been reported, meeting the threshold for High severity.
Plain-English summary
Sagent Pharmaceuticals Inc is recalling Nafcillin for Injection, USP (NDC 25021-141-99), a 10 gram per Pharmacy Bulk Package injectable antibiotic. Approximately 370,200 bottles were distributed nationwide.
The recall was issued due to lack of assurance of sterility in the affected product. This injectable medication is used in hospital and clinical settings for intravenous administration of antibiotics.
Affected product lots include NFT101 (expiration 5/31/2024), NFT201 and NFT202 (expiration 2/28/2025), and NFT203 and NFT204 (expiration 5/31/2025).
Healthcare facilities and pharmacies should verify their inventory against the identified lot numbers and expiration dates. Additional information regarding this recall is available from Sagent Pharmaceuticals or the FDA.
The recalled product
- Product
- Nafcillin for Injection, USP, 10 gram per Pharmacy Bulk Package, Rx only, Mfd. for SAGENT Pharmaceuticals, Schaumburg, IL 60195. NDC: 25021-141-99
- Manufacturer
- Sagent Pharmaceuticals Inc
- Category
- Drug — Injectable Antibiotic
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot: NFT101
- EXP: 5/31/2024
- Lots: NFT201
- NFT202
- EXP: 2/28/2025
- Lots: NFT203
- NFT204
- EXP: 5/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27